Sugi Predict

Sugi Predict / Compounds / SCHEMBL2569247

SCHEMBL2569247

SCHEMBL2569247

COC(=O)c1ccc2[nH]nc(I)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ MAP2K4 P45985 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ STAT3 P40763 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ FLT3 P36888 1/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ KIF11 P52732 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ GPR84 Q9NQS5 1/20 0.45
▸ CREBBP Q92793 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159599 1.00 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10MAP2K4
SCHEMBL2671519 0.88 MAP2K4 (0.54) KDM4EALDH1A1HPGDHSD17B10MAP2K4
SCHEMBL30159476 0.88 MAP2K4 (0.54) KDM4EALDH1A1HPGDHSD17B10MAP2K4
SCHEMBL29925789 0.84 HCRTR1 (0.57) KDM4EALDH1A1HPGDHSD17B10NPC1
SCHEMBL30076914 0.84 GABRA1 (0.53) KDM4EALDH1A1HPGDHSD17B10MAP2K4
SCHEMBL17514133 0.84 HCRTR1 (0.57) KDM4EALDH1A1HPGDHSD17B10NPC1
SCHEMBL16929779 0.83 JAK2 (0.58) KDM4EALDH1A1HPGDHSD17B10MAP2K4
SCHEMBL2671105 0.83 MAP2K4 (0.52) KDM4EALDH1A1HPGDHSD17B10MAP2K4
SCHEMBL1501529 0.83 KDM4E (0.55) KDM4EALDH1A1HPGDHSD17B10MAP2K4
SCHEMBL15479089 0.83 KIF11 (0.45) ALDH1A1HPGDMAP2K4KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 — — US disclosed
WO-2025106722-A1 INHIBITORS OF STK33, RET, CLK, AND/OR RELATED KINASES AND METHODS USING SAME BAYLOR COLLEGE OF MEDICINE (US) 2025-05-22 — — WO disclosed
CN-115427035-B ENL/AF9 YEATS inhibitors 洛克菲勒大学 2025-04-22 — — CN disclosed
US-20240158355-A1 BET SUBFAMILY INHIBITORS AND METHODS USING SAME BAYLOR COLLEGE MEDICINE (US) 2024-05-16 — — US disclosed
EP-3925956-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2024-04-10 — — EP disclosed
US-20240066027-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2024-02-29 — — US disclosed
EP-4255904-A2 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2023-10-11 — — EP disclosed
US-20230278991-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-09-07 — — US disclosed
US-20230278991-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-09-07 — — US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 — — US disclosed
WO-2012095781-A1 INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-07-19 — — WO disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 — — WO disclosed
US-20120108619-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS PFIZER INC 2012-05-03 — — US disclosed
WO-2012056372-A1 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS PFIZER INC. (US) 2012-05-03 — — WO disclosed
WO-2011123937-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2011-10-13 — — WO disclosed
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 — — US disclosed
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 — — US disclosed
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 — — US disclosed
EP-1851203-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-11-07 — — EP disclosed
WO-2006086255-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158355-A1 BET SUBFAMILY INHIBITORS AND METHODS USING SAME BRDT, BRD3, BRD2 KDM4E 147/4885ALDH1A1 3781/4885HPGD 1375/4885
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 KDM4E 3230/4885ALDH1A1 1373/4885HPGD 475/4885
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP KDM4E 4100/4885ALDH1A1 1023/4885HPGD 474/4885
US-20120108619-A1 N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS ACACA, ACACB, COASY KDM4E 2570/4885ALDH1A1 158/4885HPGD 619/4885
US-20230278991-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, GIPR KDM4E 3200/4885ALDH1A1 626/4885HPGD 1309/4885
US-20240066027-A1 NOVEL PAR-2 INHIBITORS F2RL1, F2R, F2RL3 KDM4E 3995/4885ALDH1A1 1523/4885HPGD 238/4885
US-20080004259-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B KDM4E 1010/4885ALDH1A1 2845/4885HPGD 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.